| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -8.14 M USD | -7.73 M USD | -14.09 M USD | -17.15 M USD | -11.46 M USD | -3.89 M USD | -2.45 M USD | -2.57 M USD | -2.74 M USD | -2.70 M USD | -43164 USD | -21632 USD |
| Depreciation & Amortization | 200858 USD | 337489 USD | 343982 USD | 327910 USD | 656643 USD | 120872 USD | 2.27 M USD | 2.90 M USD | 3.22 M USD | 1.36 M USD | — | — |
| Stock-Based Compensation | 827323 USD | 1.56 M USD | 2.15 M USD | 2.62 M USD | 12.60 M USD | 1.98 M USD | 624052 USD | — | 7.08 M USD | 1.46 M USD | — | — |
| Capital Expenditures | — | — | 5180 USD | 584165 USD | 189719 USD | — | — | — | — | — | — | — |
| Cash Flow from Investing | — | — | 11667 USD | -584165 USD | 2.19 M USD | -44143 USD | -284331 USD | -3.64 M USD | -808884 USD | -6.59 M USD | — | — |
| Cash Flow from Financing | 10.58 M USD | 7.67 M USD | -1.34 M USD | 18.18 M USD | 24.90 M USD | 5.53 M USD | 1.80 M USD | 2.69 M USD | 7.05 M USD | 8.80 M USD | 48000 USD | 20500 USD |
| Dividends Paid | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock Buybacks | — | — | — | — | — | — | — | — | — | — | — | — |
| Free Cash Flow | -8.14 M USD | -7.73 M USD | -14.10 M USD | -17.73 M USD | -11.65 M USD | -3.93 M USD | — | — | — | — | — | — |
Enveric Biosciences Inc. is a biotechnology company primarily focused on developing novel small-molecule therapeutics for the treatment of cancer and neurological diseases. By leveraging advanced technologies, the company aims to address unmet medical needs through innovative pharmaceutical approaches. Enveric Biosciences engages in preclinical research that incorporates cutting-edge techniques in medicinal science, focusing particularly on indications with high demand for new therapeutic options. The company's portfolio includes both proprietary and partnered drug candidates, advancing through various stages of clinical development. As part of the healthcare sector, Enveric Biosciences plays a crucial role in the broader effort to discover and develop new treatments that can significantly improve patient outcomes. Though in early stages of development, the company’s potential contributions to biotech innovation underscore its role in driving forward progress in medical research and drug discovery within the financial markets. Based in North America, Enveric pursues collaborations with various research institutions and biotech companies to enhance its drug development processes.